临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)
minimal residual disease,317–320 320
Acute myeloid leukemia (AML)clinical features,289–291 291
cytogenetics for diagnosis and prediction,300–302 302
Acute promyelocytic leukemia (APL),291–292,323 323
ADCC see Antibody-dependent cell cytotoxicity Add-on design active control,45 45
Adjuvant therapy advantages over neoadjuvant therapy chronic drug administration,276 276
metastasis risk reduction,275 275
meanings of adjuvant,276–277 277
neoadjuvant therapy advantages see Neoadjuvant therapy overview,271–272 272
Adverse event (AE)adverse drug reaction,425 425
anticipation in clinical study design,419–420 420
cause-and-effect data from raw data,435–436 436
classification anticipated versus unanticipated,431–435 435
disease induction versus study drug induction,426–427 427
statistician considerations,427 427
Dear Healthcare Professional letters in risk minimization acne medications,456–457 457
appetite suppressants,457 457
birth control pills,455–456 456
dose modification,420–423 423
intent to treat analysis,427–431 431
mechanism of action and expected adverse drug reactions,473–474 474
monitoring and evaluation Case Report Form follow up reports,446–447 447
writing style,444–445 445
data capturing transmission and evaluation,445–449 449